GlassScriptPhysician profile
Harvey M Spector
NPI 1881691541
$14,688.12
in general payments reported to CMS, 2019-2025
51 companies · $1,784 in 2025
The $1,784 reported for 2025 was more than what 93% of Adult Medicine providers received nationally (typical 2025 total: $127).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,352 · 2020: $1,118 · 2021: $2,030 · 2022: $2,058 · 2023: $1,576 · 2024: $1,770 · 2025: $1,784.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,130 · Education: $0.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,129.94 |
| Education | $0.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,224.67 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $1,577.38 | 2019-2025 | Ozempic |
| Abbvie INC. | $1,264.35 | 2019-2025 | Qulipta, Ubrelvy, Vraylar |
| Janssen Pharmaceuticals, INC | $802.77 | 2019-2023 | Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $708.89 | 2019-2024 | Xifaxan, Trulance |
| Amgen INC. | $644.51 | 2019-2025 | Otezla, Krystexxa, Repatha |
| Sanofi-Aventis U.S. LLC | $629.78 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $438.87 | 2019-2025 | Jardiance, Jascayd, Spiriva Respimat |
| Teva Pharmaceuticals USA, INC. | $407.82 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $388.67 | 2019-2025 | Belsomra, Steglatro, Capvaxive |
| Pfizer INC. | $365.77 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $363.06 | 2021-2025 | |
| Lilly USA, LLC | $345.86 | 2019-2022 | |
| Allergan, INC. | $256.32 | 2019 | |
| Phathom Pharmaceuticals, INC. | $255.34 | 2024 | Voquezna |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harvey Spector listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.